Effient [prasugrel] has received Class I recommendations for use in angioplasty, ST-elevation myocardial infarction or severe heart attack
Keyword(s):
Class I
◽
2020 ◽
2016 ◽
Vol 68
(18)
◽
pp. B47
Keyword(s):
2015 ◽
Vol 5
(4)
◽
pp. 217-222
◽
Keyword(s):
2013 ◽
Vol 13
(3)
◽
pp. 270-276
◽